Latest News and Press Releases

Total Revenue of $71.3 million for FY2024, growing 45% over FY2023; Gross margins of 78% for FY2024, up 5% points over FY2023; FY2025 Total Revenue Guidance of $92-95 million; Conference Call and...

LOUISVILLE, Colo., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced Scott Hutton, Chief Executive Officer, and Robin Cowie,...

LOUISVILLE, Colo., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the fourth...

LOUISVILLE, Colo., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced its preliminary financial results for the fourth quarter...

LOUISVILLE, Colo., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, announced a new post-market clinical...

Q3 2024 revenue grew 35% over Q3 2023 to $18.2 million; Q3 2024 gross profit margin of 77.0%, up from 76.1% in Q3 2023; Q3 2024 Net loss improved by 6% compared to Q3 2023; Conference Call and...

LOUISVILLE, Colo., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive...

BOULDER, Colo., March 26, 2019 (GLOBE NEWSWIRE) -- Biodesix® will release new data demonstrating the potential diagnostic utility of a blood-based test for patients with resistance to osimertinib,...

Researchers Present New Data from Blood-Based Proteomic Test in Biomarkers and Immune Monitoring at SITC 2018   BOULDER, Colo. and WASHINGTON, Nov. 12, 2018 (GLOBE NEWSWIRE) -- Researchers with...

Noninvasive Test to Rule Out Cancer Expected to Lower Patient Anxiety and Costs BOULDER, Colo., Oct. 30, 2018 (GLOBE NEWSWIRE) -- Biodesix® today provided an update on the Observational Registry...